These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6739537)

  • 21. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
    Abuzzahab FS; Zimmerman RL
    J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylphenidate augmentation therapy in schizophrenia.
    Carpenter MD; Winsberg BG; Camus LA
    J Clin Psychopharmacol; 1992 Aug; 12(4):273-5. PubMed ID: 1527231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic effect of buprenorphine in schizophrenia.
    Schmauss C; Yassouridis A; Emrich HM
    Am J Psychiatry; 1987 Oct; 144(10):1340-2. PubMed ID: 3310672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of trees drawn by patients with paranoid schizophrenia.
    Inadomi H; Tanaka G; Ohta Y
    Psychiatry Clin Neurosci; 2003 Aug; 57(4):347-51. PubMed ID: 12839513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diazepam in high doses is effective in schizophrenia.
    Nestoros JN; Suranyi-Cadotte BE; Spees RC; Schwartz G; Nair NP
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):513-6. PubMed ID: 6891818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The use of the brief psychiatric rating scale (BPRS) by overall and gorham for the diagnosis of acute paranoid psychoses: evaluation of a german translation of the BPRS (author's transl)].
    Mombour W; Kockott G; Fliege K
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Sep; 8(5):279-88. PubMed ID: 1233522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EEG and clinical profile of a synthetic analogue of methionine-enkephalin - FK 33-824.
    Krebs E; Roubicek J
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Jan; 12(1):86-93. PubMed ID: 368820
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder.
    Winter M; Lehmann E; Scholz OB
    Neuropsychobiology; 1984; 12(2-3):115-21. PubMed ID: 6527751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects.
    Watson SJ; Berger PA; Akil H; Mills MJ; Barchas JD
    Science; 1978 Jul; 201(4350):73-6. PubMed ID: 351804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
    Kurland AA; McCabe OL; Hanlon TE; Sullivan D
    Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Des-enkephalin-gamma-endorphin in the treatment of schizophrenia.
    Azorin JM; Blum A; Charbaut J; Escande M; Granier F; Huber JP; Metzger JY; Richou H; Sitsen A; Van Amerongen P
    Int Clin Psychopharmacol; 1990 Jul; 5(3):205-15. PubMed ID: 2230065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.
    Csernansky JG; Riney SJ; Lombrozo L; Overall JE; Hollister LE
    Arch Gen Psychiatry; 1988 Jul; 45(7):655-9. PubMed ID: 3289523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methysergide decreases prolactin release after FK 33-824 [Tyr-D-Ala-Gly-MePhe-Met(o)-ol], a potent analogue of methionine enkephalin. A study in man.
    Jungkunz G; Nedopil N; Rüther E
    Psychopharmacology (Berl); 1984; 83(2):210-2. PubMed ID: 6431476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relief of chronic intractable hallucinosis in residual schizophrenia with oxazepam.
    Lewis R
    Am J Psychiatry; 1985 Jun; 142(6):785. PubMed ID: 4003612
    [No Abstract]   [Full Text] [Related]  

  • 38. Antipsychotic effect of milieu in the acute treatment of schizophrenia.
    Cohen S; Khan A
    Gen Hosp Psychiatry; 1990 Jul; 12(4):248-51. PubMed ID: 2376324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients.
    Verhoeven WM; van Ree JM; Heezius-van Bentum A; de Wied D; van Praag HM
    Arch Gen Psychiatry; 1982 Jun; 39(6):648-54. PubMed ID: 7092498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose diazepam in schizophrenia.
    Beckmann H; Haas S
    Psychopharmacology (Berl); 1980; 71(1):79-82. PubMed ID: 6779328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.